TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24512981
Drug: Doxorubicin 75
Normalized name: DOXOrubicin 75 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 75 mg/m2 i.v., q3wk or doxorubicin 60 mg/m2 plus ifosfamide (6‐9 g/m2) i.v. q3wk (Arm B)
Study: 20656163
Drug: Intracameral epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracameral epinephrine (0.2 mL, 1:5000 solution)
Study: 18635256
Drug: Methotrexate plus
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate plus etanercept 50 mg/week
Study: 18635256
Drug: Methotrexate alone
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate alone (titrated from 7.5 mg to 20 mg/week)
Study: 15766304
Drug: Levetiracetam (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (500 to 1000 mg titrated to 2000 mg/day, maximum 3000 mg/day)
Study: 12186343
Drug: Initial preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial preparation (IP) including scaling and root planing followed by apically repositioned flap surgery
Study: 12186343
Drug: Initial preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial preparation (IP) only
Study: 10568044
Drug: Tardyferon (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tardyferon (1 tablet per day for two months starting on the 4th day after delivery)
Study: 10568044
Drug: Tardyferon Fol
Normalized name: Niva-Fol
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tardyferon Fol (1 tablet per day for two months starting on the 4th day after delivery)
Study: 7517238
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication (Control group)
Study: 2009366
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg per day cyclosporine A (CyA) from day -1 to day +20 after bone marrow transplant (BMT)
Study: 2009366
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg per day cyclosporine A (CyA) from day -1 to day +20 after bone marrow transplant (BMT)
Study: 2009366
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg per day cyclosporine A (CyA)
Study: 2009366
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg per day cyclosporine A (CyA)
Study: 7171417
Drug: Pre-treatment with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment with tubocurarine
Study: 24593664
Drug: Topical petroleum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical petroleum jelly (2 g/kg, twice daily until 34 weeks of gestation)
Study: 24593664
Drug: No topical
Normalized name: Altreno Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No topical petroleum jelly treatment (Control)
Study: 10475357
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg Pygeum africanum extract twice daily
Study: 10475357
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Pygeum africanum extract once daily
Study: 31117088
Drug: Enarodustat 2
Normalized name: Enarodustat
DrugBank: Enarodustat (DB14985)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Enarodustat 2 mg
Study: 31117088
Drug: Enarodustat 4
Normalized name: Enarodustat
DrugBank: Enarodustat (DB14985)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Enarodustat 4 mg
Study: 31117088
Drug: Enarodustat 6
Normalized name: Enarodustat
DrugBank: Enarodustat (DB14985)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Enarodustat 6 mg
Study: 31117088
Drug: Enarodustat (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enarodustat (any dose)
Study: 19158801
Drug: 5% albumin
Normalized name: Flexbumin 5% Albumin (Human) Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% albumin (10 ml kg(‐1))
Study: 19158801
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (NS) (10 ml kg(‐1))
Study: 17680182
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural ropivacaine at 6 mg x h(‐1) (group R‐6)
Study: 17680182
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural ropivacaine at 18 mg x h(‐1) (group R‐18)
Study: 17680182
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural ropivacaine at 12 mg x h(‐1)
Study: 29392749
Drug: Mobile application-based
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile application-based treatment for urinary incontinence
Study: 20443719
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol valerate (2 mg) with or without medroxyprogesterone acetate (5 mg)
Study: 17355218
Drug: Cisplatin/pemetrexed combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin/pemetrexed combination chemotherapy
Study: 17355218
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy options
Study: 17355218
Drug: Newest biologically
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newest biologically targeted therapies
Study: 2260727
Drug: Borage oil
Normalized name: Borage oil
DrugBank: Borage oil (DB11238)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Borage oil (4.5 ml/day for 4 weeks)
Study: 2260727
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (4.5 ml/day for 4 weeks)
Study: 2260727
Drug: Control (safflower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (safflower oil, 4.5 ml/day for 4 weeks)
Study: 27292093
Drug: Biological treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological treatments for psoriasis (specifics on dosage and duration not provided)
Study: 15897799
Drug: Baseline plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline plasma interleukin (IL)-6 and soluble tumor necrosis factor receptor (sTNFR) 1 concentrations
Study: 15897799
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of selected baseline proinflammatory cytokine concentrations and APACHE II score
Study: 2540786
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of lisinopril (10 mg)
Study: 2540786
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of lisinopril (5 mg)
Study: 345994
Drug: Lynestrenol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lynestrenol (10 mg per day from the 10th to the 24th day of the cycle)
Study: 23768094
Drug: Mediterranean diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean diet (specific details on dosage and duration not available)
Study: 9381383
Drug: Lovastatin (40-60-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (40-60-80 mg daily)
Study: 9381383
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no hypolipidemic therapy)
Study: 3094207
Drug: Conventional azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Conventional azathioprine and low-dose prednisolone (AP)
Study: 3094207
Drug: Biopsies several
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biopsies several years after transplantation (AP therapy)
Study: 30343314
Drug: AR-301 (human
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR-301 (human monoclonal antibody)
Study: 23334785
Drug: 810-nm continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 810-nm continuous wave low-level laser therapy (LLLT)
Study: 22183484
Drug: budesonide/formoterol combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: budesonide/formoterol combination
Study: 16365224
Drug: Dornase alfa
Normalized name: Dornase Alfa
DrugBank: Dornase alfa (DB00003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dornase alfa (2.5 mg)
Study: 16365224
Drug: Hypotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotonic saline solution (5 mL)
Study: 9604976
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (FPANS), 200 microg twice a day
Study: 9604976
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate aqueous nasal spray, 200 microg twice a day
Study: 7699845
Drug: SY5555 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY5555 administered at daily doses between 3.4-10 mg/kg, t.i.d., for 3-14 days
Study: 2773845
Drug: Iron-folic acid
Normalized name: folic acid / iron carbonyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-folic acid supplements for 60 days
Study: 411668
Drug: Spironolactone (Aldactone)
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone (Aldactone) 400 mg/day
Study: 411668
Drug: Spironolactone (Aldactone)
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone (Aldactone) 300 mg/day
Study: 411668
Drug: Spironolactone (Aldactone)
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone (Aldactone) 200 mg/day
Study: 411668
Drug: Spironolactone (Aldactone)
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone (Aldactone) 100 mg/day
Study: 21967490
Drug: Posaconazole 200mg
Normalized name: POSACONAZOLE 200MG EC TAB
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole 200mg once daily for 24 weeks
Study: 21967490
Drug: Posaconazole 400mg
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole 400mg once daily for 24 weeks
Study: 21967490
Drug: Posaconazole 400mg
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole 400mg once daily for 12 weeks
Study: 21967490
Drug: Terbinafine 250mg
Normalized name: terbinafine 250 MG
DrugBank: Terbinafine (DB00857)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terbinafine 250mg once daily for 12 weeks
Study: 15802774
Drug: Bisphosphonates (first-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonates (first-line drugs)
Study: 15802774
Drug: Active vitamin
Normalized name: OCTOCRYLENE 70 mg in 1 mL / HOMOSALATE 50 mg in 1 mL / OCTISALATE 50 mg in 1 mL / AVOBENZONE 30 mg in 1 mL TOPICAL CREAM [Garnier SkinActive Vitamin(E) C UV Brightening Daily Broad Spectrum SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active vitamin D3 and vitamin K2 (second-line drugs)
Study: 10320242
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive operation (L-shaped sternotomy)
Study: 30530975
Drug: 20 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg bryostatin
Study: 30530975
Drug: 40 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 μg bryostatin
Study: 25623412
Drug: SBIRT intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SBIRT intervention (online Screening, Brief Intervention, and Referral to Treatment)
Study: 24890141
Drug: KumaFix fixation
Normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: KumaFix fixation system (treatment group, n = 23)
Study: 22571474
Drug: Probiotic therapy
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic therapy (VSL#3), n=31
Study: 20602781
Drug: Pregabalin 300
Normalized name: pregabalin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 300 mg daily
Study: 20602781
Drug: Pregabalin 450
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 450 mg daily
Study: 21639874
Drug: Pregabalin 600
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 600 mg daily
Study: 17613582
Drug: Psychosocial intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychosocial intervention (up to 16 meetings over six months, approximately weekly for 12 weeks, followed by tri-weekly sessions for another 12 weeks, lasting approximately 1 hour each)
Study: 16097635
Drug: D2 receptor
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D2 receptor binding in the caudate nucleus and putamen in the PD-JPD group
Study: 16097635
Drug: D2 receptor
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D2 receptor binding in the putamen in the MSA-PSP group
Study: 16097635
Drug: D2 receptor
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D2 receptor binding in the PD-JPD group
Study: 16097635
Drug: D2 receptor
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D2 receptor binding in the MSA-PSP group
Study: 12033702
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (250 ml, approximately 23 g of ethanol) with the noon meal
Study: 7576329
Drug: Intervention community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention community (STD treatment)
Study: 7576329
Drug: Comparison community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison community (no STD treatment)
Study: 6980774
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tilcotil (Ro 12-0068) daily
Study: 6980774
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg aspirin 4-times daily
Study: 29150250
Drug: Amlodipine 5mg
Normalized name: LEVAMLODIPINE 5MG TAB
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5mg + Losartan 100mg + Rosuvastatin 20mg (A/L/R 5/100/20)
Study: 29150250
Drug: Amlodipine 5mg
Normalized name: LEVAMLODIPINE 5MG TAB
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5mg + Losartan 100mg (A/L 5/100)
Study: 29150250
Drug: Losartan 100mg
Normalized name: LOSARTAN 100MG TAB
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan 100mg + Rosuvastatin 20mg (L/R 100/20)
Study: 24943855
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg 0.5% prilocaine
Study: 24943855
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg 0.5% prilocaine plus 50 mg dexketoprofen
Study: 24943855
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg 0.5% prilocaine plus 8 mg dexamethasone
Study: 10836288
Drug: Citalopram (highly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (highly selective serotonin uptake inhibitor)
Study: 10836288
Drug: TTCAs (adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTCAs (adrenergic tetracyclic antidepressants)
Study: 9342579
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg valsartan, once-daily for 8 days
Study: 27921517
Drug: 17 alpha-hydroxyprogesterone
Normalized name: 17 alpha-hydroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 alpha-hydroxyprogesterone caproate (17-OHPC) weekly injections, full compliance (100%)
Study: 27921517
Drug: 17 alpha-hydroxyprogesterone
Normalized name: 17 alpha-hydroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 alpha-hydroxyprogesterone caproate (17-OHPC) weekly injections, partial compliance (40-80%)
Study: 17925589
Drug: Tolvaptan 60-240
Normalized name: tolvaptan 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan 60-240 mg (study 1)
Study: 17925589
Drug: Tolvaptan 180-480
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tolvaptan 180-480 mg (study 2)
Study: 11702012
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (ribavirin + interferon-alpha)
Study: 8483846
Drug: Procaterol (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaterol (oral administration)
Study: 8483846
Drug: Procaterol (tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaterol (tablet administration)
Study: 3120928
Drug: Oral cyclosporin
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclosporin (5 mg/kg/day) for 12 weeks
Study: 27611703
Drug: 2 g/kg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/kg/week IVIG (Arm A)
Study: 27611703
Drug: 1 g/kg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/kg/week IVIG + 0.5 mg/kg/day prednisone (Arm B)
Study: 20864862
Drug: High-frequency, low-magnitude
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-frequency, low-magnitude vibration (30 Hz, 0.3 g peak acceleration) for 10 min/day for 6 months
Study: 20032168
Drug: Exercise prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise prescription
Study: 14660460
Drug: Latanoprost 0.005%
Normalized name: LATANOPROST 0.005% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost 0.005% monotherapy once daily for 6 months
Study: 14660460
Drug: Dual ocular
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual ocular hypotensive therapy
Study: 18703470
Drug: PCI plus
Normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCI plus optimal medical therapy
Study: 31169029
Drug: Family-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-assisted therapy from a family member trained by a physiotherapist
Study: 29954931
Drug: Prednisone/sirolimus/calcineurin-inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone/sirolimus/calcineurin-inhibitor
Study: 20032790
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (IIT) - maintenance of blood glucose between 80 mg/dL and 110 mg/dL with continuous insulin infusion
Study: 20032790
Drug: Conventional glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glycemic therapy (CGT) - maintenance of blood glucose below 180 mg/dL with subcutaneous insulin and insulin infusion if blood glucose levels exceeded 220 mg/dL
Study: 20032790
Drug: Conventional glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glycemic therapy (CGT)
Study: 11939911
Drug: Four-drug multimodal
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-drug multimodal regimen (dexamethasone 4 mg, ondansetron 4 mg, droperidol 1.25 mg, metoclopramide 10 mg i.v.)
Study: 11939911
Drug: Low-dose propofol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose propofol infusion (1 mg/kg/h during the operation and the first 4 postoperative hours)
Study: 11939911
Drug: Four-drug multimodal
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-drug multimodal regimen (M group)
Study: 11939911
Drug: Low-dose propofol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose propofol infusion (P group)
Study: 9830641
Drug: Inferior alveolar
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inferior alveolar nerve block + intraosseous injection (0.9 mL of 2% lidocaine with 1:100,000 epinephrine)
Study: 9830641
Drug: Inferior alveolar
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inferior alveolar nerve block + mock intraosseous injection
Study: 1105543
Drug: Fluphenazine 0.5
Normalized name: fluphenazine 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluphenazine 0.5 mg/nortriptyline 10 mg three times daily
Study: 1105543
Drug: Promazine 50
Normalized name: promazine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promazine 50 mg three times daily
Study: 29105476
Drug: Traditional traction,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional traction, massage and intermediate frequency electro therapy
Study: 19029171
Drug: Routine glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine glucose lowering therapy
Study: 15365658
Drug: 200 IU
Normalized name: Vitamin E 200 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 IU calcitonin nasal spray with calcium (500 mg) and vitamin D (200 IU)
Study: 15365658
Drug: Calcium (500
Normalized name: calcium gluconate 45 mg calcium (500 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (500 mg) and vitamin D (200 IU) alone
Study: 15365658
Drug: 200 IU
Normalized name: Vitamin E 200 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 IU calcitonin nasal spray
Study: 1544845
Drug: BW12C (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: BW12C (20 mg/kg to 50 mg/kg) with mitomycin C
Study: 1544845
Drug: BW12C (maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: BW12C (maintenance infusion of 4-6 mg/kg/hr) with mitomycin C
Study: 12786622
Drug: Intra-arterial injection
Normalized name: METHOTREXATE 25 mg in 1 mL INTRA-ARTERIAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-arterial injection of radioactive iodine mixed with Lipiodol
Study: 8931220
Drug: Intravenous PGE1
Normalized name: PGE1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous PGE1 (720 micrograms/day for 3 days)
Study: 1576624
Drug: Loracarbef (200‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loracarbef (200‐mg capsule BID or 15 mg/kg/day suspension)